Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Mutant RAS"'
Publikováno v:
Biomolecules, Vol 11, Iss 236, p 236 (2021)
Biomolecules
Biomolecules
RAS oncogenes are amongst the most commonly mutated proteins in human cancers. They regulate a wide range of effector pathways that control cell proliferation, survival, differentiation, migration and metabolic status. Including aberrations in these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::036ab6c9d121c23b0ece73d0926d6a2a
https://www.mdpi.com/2218-273X/11/2/236
https://www.mdpi.com/2218-273X/11/2/236
Publikováno v:
Cancer Metastasis Reviews
The genetic alterations in cancer cells are tightly linked to signaling pathway dysregulation. Ras is a key molecule that controls several tumorigenesis-related processes, and mutations in RAS genes often lead to unbiased intensification of signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d8728c303cd35b483fb4093c556362
https://pubmed.ncbi.nlm.nih.gov/32648136
https://pubmed.ncbi.nlm.nih.gov/32648136
Autor:
Apostolos Zaravinos
Publikováno v:
Critical Reviews™ in Oncogenesis. 22:283-301
The RAS oncogenes are the most commonly mutated genes across human cancers. This review is a look back at the discovery of the RAS genes, how we came to understand their function, and how these oncogenes are aberrantly activated, driving cancer devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba73ae4b7b05a20f68b873851005ca05
https://doi.org/10.1615/critrevoncog.2017024695
https://doi.org/10.1615/critrevoncog.2017024695
Autor:
Sarah E. Kovar, Christopher Morris, Daniel M. Ketcha, Cody Fourman, Brandon Williams, Christine Kinstedt, Kwang-Jin Cho
Publikováno v:
Bioorg Med Chem Lett
Ras proteins are small GTPases which regulate cellular proliferation, differentiation, and apoptosis. Constitutively active mutant Ras are expressed in ~15-20% human cancers, and K-Ras mutations account for ~85% of all Ras mutations. Despite the sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::805be2cea64bb99852a56df399568850
https://pubmed.ncbi.nlm.nih.gov/32276831
https://pubmed.ncbi.nlm.nih.gov/32276831
Autor:
Anda Trifan
Publikováno v:
Biophysical Journal. 120:233a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca3c033c7ff304fe0e17f2b1d970fd3c
https://doi.org/10.1016/j.bpj.2020.11.1544
https://doi.org/10.1016/j.bpj.2020.11.1544
Autor:
Wisut Lamlertthon, Edward Gane, Josep M. Llovet, Baek-Yeol Ryoo, Thomas Yau, Watana Sukeepaisarnjaroen, Yuk Ting Ma, Judit Kocsis, Jean-François Dufour, René Gerolami, Winnie Yeo, Jean-Frédéric Blanc, Philippe Merle, Markus Peck-Radosavljevic, Su Pin Choo, Karl Heinz Weiss, Heiko Krissel, Satawat Thongsawat, Vincenzo Mazzaferro, Paul Ross, Chia Jui Yen, Thong Dao, Ho Yeong Lim, Michael Teufel
Publikováno v:
Hepatology. 64:601-810
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e44c5829f074daaf2b5027d5b187969f
https://doi.org/10.1002/hep.28799
https://doi.org/10.1002/hep.28799
Autor:
Shuxing Zhang, Zhi Tan
Publikováno v:
Mini-Reviews in Medicinal Chemistry. 16:345-357
For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers. However, targeting this oncogene has been challenging and no Ras inhibitors are on the market to date. Latel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a11d119ab7d715aa52b6df118218c6
https://doi.org/10.2174/1389557515666151001154111
https://doi.org/10.2174/1389557515666151001154111
Publikováno v:
Life Sciences. 257:118141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8a28cac50dc30f91bdb5ac53eee6af4
https://doi.org/10.1016/j.lfs.2020.118141
https://doi.org/10.1016/j.lfs.2020.118141
Autor:
Rumeesa Rais, Laurence Booth, Alshad S. Lalani, Irmina Diala, Andrew Poklepovic, Richard E. Cutler, Jane L. Roberts, Paul Dent
Cancers expressing mutant RAS are associated with a weaker response to chemotherapy and a shorter overall patient survival. We have demonstrated that the irreversible inhibitor of ERBB1/2/4, neratinib, inhibits ERBB1/2/4 and causes their internalizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e96fe4b09ab4d468f65fcb232513ef0
https://europepmc.org/articles/PMC6343717/
https://europepmc.org/articles/PMC6343717/
